

OBERWEIS MICRO-CAP FUND INVESTOR CLASS (OBMCX) INSTITUTIONAL CLASS (OMCIX)

4Q 2017

AVERAGE ANNUAL TOTAL RETURNS (as of December 31, 2017)

	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Since Inception 1/1/1996	Gross/Net Expense Ratio*
Oberweis Micro-Cap Fund Institutional Class (OMCIX)**	3.54%	28.24%	28.24%	19.54%	21.17%	8.08%	10.85%	1.28%/1.28%
Oberweis Micro-Cap Fund Investor Class (OBMCX)	3.47%	27.90%	27.90%	19.24%	20.87%	7.81%	10.57%	1.54%/1.54%
Russell Microcap Growth Index	0.93%	16.65%	16.65%	6.22%	13.82%	7.23%	N/A	
Russell 2000 Growth Index	4.59%	22.17%	22.17%	10.28%	15.84%	9.19%	7.20%	

*December 31, 2017 unaudited data. The gross expense ratio includes expense off set arrangements and expense reimbursements. Oberweis Asset Management, Inc. (OAM), the Fund's investment advisor is contractually obligated through April 30, 2018 to reduce its management fees or reimburse OBMCX to the extent that total ordinary operating expenses, as defined, exceed in any one year the following amounts expressed as a percentage of each Fund's average daily net assets: 1.8% of the first \$50 million; plus 1.6% of average daily net assets in excess of \$50 million and for OMCIX 1.55% of the first \$50 million; plus 1.35% of average daily net assets in excess of \$50 million. The annual expense ratio will reflect a blend of both the old and new expense reimbursement arrangements in effect for 2017.

**Institutional Class shares OMCIX performance information was calculated using the historical performance of Investor Class shares for periods prior to May 1, 2017.

Performance data shown represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate, so that you may have a gain or loss when shares are sold. Current performance may be higher or lower than quoted. Visit us online at oberweis.funds.com for the most recent month-end performance. Before investing, consider the Fund's investment objectives, risks, charges, and expenses. To obtain a copy of the prospectus or summary prospectus containing this and other information, please visit our website at oberweisfunds.com or call 800-323-6166. Read it carefully before investing. The Oberweis Funds invest in rapidly growing smaller and medium-sized companies that may offer greater return potential. However, these investments often involve greater risks and volatility. Foreign investments involve greater risks than U.S. investments, including political and economic risks and the risk of currency fluctuations. There is no guarantee that the Funds can achieve their objectives.

The Russell 2000 Index measures the performance of approximately 2,000 companies with small-market capitalizations. The Russell 2000 Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted earnings growth rates. The Russell Microcap Growth Index measures the performance of those Russell Micro Cap companies with higher price-to-book ratios and higher forecasted growth values. The performance data includes reinvested dividends.

The Russell Microcap Index is represented by the smallest 1,000 securities in the small cap Russell 2000 Index plus the next 1,000 securities. Each index is an unmanaged group of stocks, whose performance does not reflect the deduction of fees, expenses or taxes.

The Oberweis Funds are distributed by Oberweis Securities, Inc. Member: FINRA & SIPC.

The Quarter and Year in Review

The Oberweis Micro-Cap Fund had another strong year in 2017, returning 27.90% versus 22.17% for the Russell 2000 Growth Index, an outperformance of 573 basis points. The Fund also outperformed the Russell Microcap Growth Index in 2017 by 1,125 basis points. During the fourth quarter, the Fund returned 3.47% versus 4.59% for the Russell 2000 Growth Index, a shortfall of 112 basis points. Compared to the Russell Microcap Growth Index's return of 0.93%, however, the Fund outperformed by 254 basis points.

This performance was generated in the face of mixed style and capitalization forces. Growth stocks outperformed value stocks by a wide margin during the quarter and the year¹, a reversal from 2016 which aided the portfolio from a style perspective. The portfolio's micro-capitalization focus, however, represented a headwind as larger-cap stocks outperformed small-cap stocks during the quarter and the year². In fact, the smallest capitalization quintile and stocks with capitalizations under \$1 billion – our micro-cap hunting ground – were the worst performing stocks within the Russell 2000 Growth Index itself. Additionally, biotech stocks, which returned a staggering 60% in 2017 and represented nearly 10.7% of the benchmark at the year-end, detracted from portfolio performance. We are consistently and substantially underweight biotech shares given that most companies lack earnings (and therefore the potential for earnings "surprises") and do not fit our investment philosophy.

¹ For 2017, the Russell 2000 Growth Index and the Russell 2000 Value Index returned 22.17% and 7.84%, respectively. For the fourth quarter, the Russell 2000 Growth Index and the Russell 2000 Value Index returned 4.59% and 2.05%, respectively.

² For 2017, the Russell 1000 Growth Index (a proxy for large-cap stocks) and the Russell 2000 Growth Index returned 30.21% and 22.17%, respectively. For the fourth quarter, the Russell 1000 Growth Index and the Russell 2000 Growth Index returned 7.86% and 4.59%, respectively.

³ Source: Steven G. DeSanctis, Jefferies LLC.

⁴ Source: JP Morgan Guide to the Markets.

OBERWEIS MICRO-CAP FUND INVESTOR CLASS (OBMCX) INSTITUTIONAL CLASS (OMCIX)

4Q 2017

The Quarter and Year In Review (continued)

The big surprise in 2017 was market volatility – or lack thereof. In fact, using the CBOE's VIX Index as a proxy, 2017 ranks as the "quietest" year for market volatility since 1990. During 2017, the VIX Index closed below 10 on 52 occasions, a stunning measure considering the VIX registered only nine such closes during the entire period from 1990 through 2016³. The biggest intra-year peak-to-trough decline for the S&P 500 Index during 2017, at 3.6%, was the lowest intra-year drawdown in the index since 1995⁴. We suspect a reversion to the mean could be in the offing in 2018.

Strength in equities was not limited to the U.S. in 2017, as European markets such as France, Germany, and the UK posted strong returns. Several emerging markets were also robust, led by rebounds in China and India and continued strength in Brazil. Japanese equities also performed well.

Global equities were buoyed by surprising economic and profits growth worldwide, and we believe recent data support strong economic growth in 2018. In the U.S., corporate profits accelerated in 2016 and 2017 and expectations are for continued growth in 2018 given the anticipated benefits from corporate tax reform. U.S. manufacturing PMI was stronger in 2017 than 2016, culminating in a December monthly reading that was the highest of the year. The U.S. consumer's balance sheet remains in great shape, bolstered by record net worth and historically low levels of debt service requirements. Housing is still affordably priced as mortgage rates – while higher than last year – remain at historically low levels. And despite an economic expansion nine years in the making, capital goods orders and housing starts are only at average historical levels, debunking concerns of froth or over-heating.

Furthermore, we believe the recently passed Tax Cuts and Jobs Act will fuel incremental economic growth in the short-term. Importantly, the reduction of the corporate tax rate to 21% will result in a cash flow boon for companies that should lead to increased levels of investment as at least a portion of that cash is plowed back. Furthermore, the repatriation of cash held abroad likely increases marginal spending by business on property, plant, equipment, and ultimately, jobs. The bill also allows for the immediate expensing of short-lived capital investments for the next five years to further encourage expenditures.

This corporate tax change and corresponding increase in free cash flow, as we noted last quarter, also favorably impact the valuation of U.S. stocks, particularly for small-cap companies that tend to do more business domestically than large-cap multi-nationals. We believe the upside to earnings from the tax change is not yet adequately reflected for many of our portfolio holdings. We also suspect that tax-related upward earnings estimate revisions will positively impact the flow of investment ideas for our portfolio in 2018.

More broadly, valuations (as measured by P/E's) in the U.S. are at above-average levels for both the S&P 500 Index and for our investable universe of small-cap growth companies, a fact that is discussed ad nauseam on CNBC and in the financial media these days. We would continue to caution that these above-average P/E's are against a backdrop of interest rates that are well below average levels, theoretically rendering historical P/E comparisons – which occurred during higher rate environments – less important.

That said, we believe the biggest risk to equity markets – aside from simmering and frankly unpredictable geo-political events – lies with interest rates. The Federal Reserve has now clearly moved to a tightening stance, raising rates three times in 2017 and importantly embarking on a balance sheet reduction strategy that will become increasingly impactful in 2018. Additionally, Federal Reserve Chair nominee Jerome Powell represents a potential "uncertainty" as he takes office and puts his own stamp on central bank policies. The market may be hyper-sensitive to his comments early in his tenure, particularly given that the leadership change coincides with a shift in Fed policy to a more hawkish stance after nearly a decade of easy money.

While headlines and investor risk appetites can change on a whim in the short-term, our bottom-up strategy has always been focused on investing in businesses with idiosyncratic attributes that afford the potential for earnings growth to surprise to the upside. These companies are often undergoing a transformational change or event that we believe is potentially misunderstood or underestimated by the consensus. While the earnings multiples afforded such companies can oscillate from quarter to quarter, we believe that prudent stock selection of a diversified portfolio of companies with prospects for better-than-expected earnings growth is likely to outperform the broader market over the long-term.

Fund Highlights

As of December 31, 2017, the Fund was 95.3% invested in 92 different positions. The Fund had its largest weightings in producer durables (22.4% average weighting during the quarter versus 15.7% for the Russell 2000 Growth Index), technology (20.9% versus 19.8%), and consumer discretionary (17.0% versus 15.7%). The Fund was most underweight healthcare (16.5% versus 23.1%), materials (4.8% versus 8.6%) and utilities (0.0% versus 2.3%).

In the fourth quarter the Fund benefited from favorable stock selection in technology (where our holdings returned 6.39% versus a 1.93% return for the benchmark's technology holdings) and materials (18.07% versus 6.95%). Performance was negatively impacted by stock selection in financial services (-3.80% versus 3.75%) and producer durables (3.85% versus 4.81%). From a capitalization standpoint, the Fund's substantial exposure to the smallest capitalization quintile in the Russell 2000 Growth Index negatively impacted performance by 125 basis points.

Key Benefits

The Micro-Cap Fund invests at least 80% of its net assets in the securities of very small companies which, at the time of purchase, have a market capitalization of less than or equal to \$600 million or are within the range of companies represented in the Russell Micro-Cap Growth Index, whichever is greater. This is an effort to capture the exceptional growth potential of emerging companies in the earliest and most dynamic phase of their development.

The potential key benefits of the Micro-Cap Fund are:

- Access to one of the least efficient segments of the equity market
- Potential for significant alpha over a full market cycle
- Combines empirically-proven Behavioral Finance principles with the very best of fundamental bottom-up research
- Disciplined and repeatable investment process managed by a passionate and experienced investment team
- Fundamental research process specifically designed to efficiently discover micro-cap companies that are misunderstood by traditional Wall Street research analysts
- Exposure to micro-cap companies offering the potential for earnings growth that differs from consensus expectations
- Diversified portfolio with a focus on risk management

The Oberweis Funds invest in rapidly growing smaller and medium sized companies which may offer greater return potential. However, these investments often involve greater risks and volatility. There is no guarantee that the portfolios can achieve their objectives.

Minimum Investment:

Oberweis Micro-Cap Fund Investor Class (OBMCX): \$1,000 non-IRA, \$500 IRA

Oberweis Micro-Cap Fund Institutional Class (OMCIX): \$1.0 million

For more information please contact:

John Collins, CIMA®

Oberweis Asset Management, Inc.

3333 Warrenville Rd., Suite 500, Lisle, IL 60532

(800) 323-6166 | (630) 577-2364 | john.collins@oberweis.net

OBERWEIS MICRO-CAP FUND INVESTOR CLASS (OBMCX) INSTITUTIONAL CLASS (OMCIX)

4Q 2017

FUND CHARACTERISTICS *(as of December 31, 2017)*

Number of Stocks	93
Weighted Market Capitalization (in millions)	\$953
Median Market Capitalization (in millions)	\$746
P/E Forward 4 Quarters (estimated)	17.2x
Long-Term Debt to Total Equity	11.0%
Return on Equity	5.0%
Cash Position	4.7%
Portfolio Turnover (2017)	91.0%
Source: Thomson Reuters Eikon	

TOP TEN HOLDINGS *(as of September 30, 2017)*

Company		Line of Business
1 AXT, Inc.	2.5%	Producer of high-performance compounds used in semiconductors
2 SkyWest, Inc.	2.3%	Operates a regional airline within North America
3 Cutera, Inc.	2.1%	Develops laser-based aesthetic products
4 Extreme Networks, Inc.	2.1%	Provides software-driven networking solutions
5 Tactile System Technology, Inc.	2.0%	Develops medical devices for the treatment of lymphedema
6 Carbonite, Inc.	1.8%	Provides cloud data protection services to consumers and businesses
7 Hudson Technologies	1.8%	Manufactures refrigerants and provides refrigerant reclamation services
8 Malibu Boats, Inc.	1.8%	Designs and manufactures sport boats
9 Spartan Motors, Inc.	1.8%	Develops and manufactures custom chassis for specialty vehicles
10 Patrick Industries, Inc.	1.7%	Manufactures building materials used primarily by the recreational vehicle industry


Top 10 holdings as a percentage of Total Net Assets. Portfolio Holdings are subject to change at any time. References to specific securities should not be construed as a recommendation to buy or sell and should not be assumed profitable. Source: Thomson Reuters Eikon

**OBERWEIS MICRO-CAP FUND
INVESTOR CLASS (OBMCX)
INSTITUTIONAL CLASS (OMCIX)**

4Q 2017


SECTOR WEIGHTINGS (as of December 31, 2017)

Consumer Discretionary	17.7%
Consumer Staples	1.5%
Energy	1.0%
Financial Services	8.5%
Health Care	16.6%
Materials & Processing	5.8%
Producer Durables	23.4%
Technology	20.8%
Utilities	0.0%
Cash	4.7%
Total	100.0%



Sector weightings as a percentage of Total Net Assets. Source: Thomson Reuters Eikon

GROWTH OF \$10,000 — WITH INCOME INVESTED (January 1, 1996–December 31, 2017)



The Russell Microcap Growth Index began on 7/3/00, and the line graph for the Index begins at the same value as the Fund on that date.

The Oberweis Aperture

Our unique, highly disciplined investment approach includes a series of eight criteria to focus our research efforts.



[READ MORE](#)

Oberweis Asset Management, Inc.

Recognized as a leading small-cap stock specialist, Oberweis has been helping institutional investors manage their assets prudently and effectively for many years.

[MEET THE TEAM](#)